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Real-Time CMR to Guide Endomyocardial Biopsy*Amy West Pollak, MD, MS, Leslie T. Cooper, JR, MDT he role of endomyocardial biopsy (EMB) forthe evaluation of cardiomyopathy and moni-toring for cardiac transplant rejection has
evolved over the past 40 years. EMB is typically done
with ﬂuoroscopic guidance and femoral or jugular
venous access for sampling the right ventricle (RV)
endocardium. Left ventricular biopsy requires arterial
access, is associated with approximately a 1 in 300 to 1
in 500 risk of stroke (1), and is therefore not routinely
done unless there is a speciﬁc concern for isolated in-
volvement of the left ventricle such as cardiac sarcoid-
osis or giant cell myocarditis, where a tissue diagnosis
would likely change prognosis ormanagement.
The current indications for EMB are on the basis of
recommendations from the 2007 American Heart As-
sociation/American College of Cardiology/European
Society of Cardiology Scientiﬁc Statement (2) and the
2011 consensus statement from the Association for
European Cardiovascular Pathology (3). The 2013
American Heart Association/American College of
Cardiology Guidelines for the Management of Heart
Failure (4) recommend considering EMB for patients
presenting with heart failure when a speciﬁc diag-
nosis is suspected that would inﬂuence therapy (Class
IIa, Level of Evidence: C) such as giant cell myocar-
ditis, fulminant lymphocytic myocarditis, or cardiac
sarcoidosis. As a result, EMB is recommended in 3
speciﬁc patient scenarios: 1) fulminant acute heart
failure: unexplained new-onset heart failure pre-
senting within 2 weeks with hemodynamic com-
promise; and 2) unexplained new-onset heart failure
(over 2 weeks to 3 months) with dilated left ventricle*Editorials published in JACC: Basic to Translational Science reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Basic to Translational Science or the American College of Cardiology.
From the Department of Cardiovascular Diseases, Mayo Clinic, Jackson-
ville, Florida. Both authors have reported that they have no relationships
relevant to the contents of this paper to disclose.and new high-grade arrhythmias (ventricular tachy-
cardia, Mobitz type II second-degree atrioventricular
block, or third-degree atrioventricular block); and
3) routine monitoring for cardiac allograft rejection. A
2013 European Society of Cardiology position state-
ment recommends extending the indications for EMB
to include chronic, idiopathic dilated cardiomyopathy
(5). EMB also has a role in the evaluation of other
patients with heart failure when inﬁltrative or storage
disorders are suspected and if noninvasive, labora-
tory, and clinical evaluation is inconclusive.
One of the main limitations of EMB is the difﬁculty
in obtaining sufﬁcient myocardial tissue affected by
the underlying pathology to make a speciﬁc histo-
logical diagnosis using the traditional ﬂuoroscopic-
guided approach and vital histological stains. The
rate of a speciﬁc diagnosis can be as low as 10% to 15%
using only RV sampling in unselected cardiomyopa-
thy patients (6). Patients presenting with acute heart
failure of <2 weeks duration have a yield of 35% on
EMB for a tissue diagnosis (7). However, in patients
with suspected myocarditis, the yield of EMB is 79%
when biventricular samples, immunoperoxidase
stains, and viral genome analysis are used for diag-
nosis (8). Taking left ventricular EMB samples with
cases of isolated left ventricular cardiomyopathy and
using immunoperoxidase and molecular diagnostic
techniques improves the yield to as high as 97.8% (9).
Multiparametric cardiac magnetic resonance im-
aging (CMR) allows for noninvasive tissue character-
ization in areas of myocardial edema, inﬂammation,
and scar using techniques such as T2 mapping, T1
mapping, and late gadolinium enhancement (LGE).
The multiparametric imaging approach is especially
useful with myocarditis, where T1 mapping can iden-
tify areas of myocardial ﬁbrosis not visible with LGE
(10). Interestingly, the diagnostic yield of EMB was
not improved when sampling areas of LGE on CMR
imaging in 1 study of patients with myocarditis (8).
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385In this issue of JACC: Basic to Translational Science,
Rogers et al. (11) studied a novel approach to EMB in a
swine animal model of myocardial infarction and
subsequent ischemic cardiomyopathy. They used
real-time CMR to identify the areas of myocardial scar
using LGE and a custom 6.5-F CMR-conditional
bioptome to remove the tissue samples. The CMR-
conditional bioptome has hinged jaws in a titanium
alloy with a copper-beryllium housing, and the cath-
eter has a dipole antennae. This design allowed for
visualization of the catheter by CMR without a sig-
niﬁcant susceptibility artifact. A second EMB proce-
dure was done using conventional ﬂuoroscopy and
commercially available bioptomes by a separate pro-
ceduralist after reviewing the LGE images. For each
animal, there were 10 to 20 biopsy specimens
obtained by both EMB procedures (CMR-guided and
traditional ﬂuoroscopy). The study compares the
diagnostic yield from EMB between the 2 procedures.SEE PAGE 376The infarct model used ﬂuorescent microspheres to
cause a focal myocardial infarction in the basal
posterolateral region. The CMR-guided EMB proce-
dure used real-time imaging with inversion recovery
sequences to identify the areas of LGE. The EMB
samples were then examined using ultraviolet light
and a dissecting microscope to determine if they
had $1 ﬂuorescent particle, indicating an accurate
sampling of the infarcted myocardium. The tradi-
tional, ﬂuoroscopy-guided EMB procedure had a
lower diagnostic yield at 56% of samples (49 of 87)
than the CMR-guided procedure (63 of 77), with a
diagnostic yield of 82% (p < 0.001).The swine infarct model results in transmural
infarction. If there is subendocardial involvement of
the myocardium, then left ventricular EMB is well
suited to obtain a histological diagnosis. However, in
cases of mid-myocardial or, in particular, isolated
subepicardial myocardial pathology, even with CMR-
guided EMB, the diagnostic yield would likely be
reduced.
The study by Rogers et al. (11) provides an exciting
view into a potential clinical use of CMR-guided EMB
that may signiﬁcantly improve the diagnostic yield of
EMB. Unfortunately, post-viral myocarditis and even
giant cell myocarditis does not uniformly affect the
endocardium. The remaining gaps to demonstrate
clinical utility can be met by demonstrating safety
and studying suspected inﬂammatory cardiomyopa-
thy in patients. The diagnostic yield with and without
CMR guidance should be assessed using both vital
stains (the Dallas Criteria for myocarditis) and the
newer immunoperoxidase and molecular diagnostic
studies. There will likely be a risk of stroke in any left
ventricular biopsy procedure, and thus a modiﬁcation
of the CMR-compatible bioptome to sample the
RV would be useful. Additionally, newer imaging se-
quences for inﬂammation such as native T1-mapping
should be evaluated with real-time CMR guidance.
The present study signiﬁcantly advances the CMR-
conditional bioptome toward clinical application in
patients with unexplained cardiomyopathy.
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